Congestive Heart Failure

CTAF

Congestive heart failure (CHF) describes the condition of fluid build-up in the body as the heart inefficiently fills with or pumps out blood. CHF results from other conditions that weaken the heart muscle including coronary artery disease, myocardial infarction, cardiomyopathy, and hypertension, and is a major public health concern.

Interventions of interest: CardioMEMS™ HF System (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis)

Date of review: September 2015

 

For questions or additional information, please contact info@icer-review.org

Associated Meetings

October 29, 2015 10:00AM-4:00PM PT

The California Endowment, Oakland, CA

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting on Thursday, October 29, 2015 to discuss the comparative effectiveness and value of two interventions for patients with congestive heart failure (CHF) – the drug Entresto (a combination of valsartan and sacubitril, Novartis AG), and the CardioMEMS HF System (St. Jude Medical).  The CardioMEMS HF System is a heart failure monitor manufactured by St. Jude Medical and approved by the FDA in May, 2014.  Entresto is a drug for the treatment of heart failure with reduced ejection fraction and was approved by the FDA on July 7, 2015.


Key Dates

Associated Materials

07/09/2015

09/11/2015 – 09/25/2015

Public comments received on the Draft Evidence Report.


09/11/2015

09/11/2015

09/11/2015

09/17/2015

Research protocol posted to Open Science Framework: https://osf.io/7awvd/


10/09/2015

10/09/2015

10/09/2015

10/29/2015

10/29/2015

10/29/2015
Webcast Recording Evidence Presentation and Public Comments

Other Materials

Policy Roundtable
Webcast Recording Deliberation and Voting